[Inhibition of renin-angiotensin-aldosterone system in heart failure, or from CONSENSUS to PARADIGM-HF].

Abstract

An historical survey is presented of mortality trials on angiotensin-aldosteron system inhibition in patients with chronic heart failure. From the CONSENSUS trial up to the PARADIGM-HF trial, ACE inhibitors/angiotensin II receptor antagonists (AT1-blockers, ARBs, sartans), along with mineralocorticoid receptor blockers, have been the gold standard of treatment. Both direct renin blocker aliskiren and dual blocker enalapril + neprilysin proved ineffective; on the other hand, the new dual inhibitor valsartan + neprilysin LCZ 696 is a new and promising therapeutic agent for future treatment of chronic heart failure.

• Authors: Jiří Vítovec, Jindřich Špinar, Lenka Špinarová
• Journal: Vnitrni lekarstvi (Vnitr Lek) Vol. 61 Issue 5 Pg. 470-4 (May 2015) ISSN: 0042-773X [Print] Czech Republic
• Vernacular Title: Inhibice systému renin-angiotenzin-aldosteron u srdečního selhání aneb od obecného souhlasu (CONSENSUS) po vzorec myšlení (PARADIGM-HF).
• PMID: 26075858 (Publication Type: Journal Article, Review)

Chemical References

• Angiotensin Receptor Antagonists
• Angiotensin-Converting Enzyme Inhibitors

Topics

• Angiotensin Receptor Antagonists (therapeutic use)
• Angiotensin-Converting Enzyme Inhibitors (therapeutic use)
• Consensus
• Heart Failure (drug therapy, metabolism)
• Humans
• Renin-Angiotensin System (drug effects)